v3.26.1
Segments
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segments
9.
Segments

The Company's single reportable segment is the business of developing and commercializing the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with IPF, non-IPF ILD, and RCC.

The accounting policies of the segment are described in Note 2 of the notes to the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q.

The following table presents reportable segment loss, including significant expense categories, attributable to the Company’s reportable segment for the periods presented:

 

 

 

Three Months Ended
March 31,

 

 

 

2026

 

 

2025

 

Chronic cough in IPF clinical trial expense

 

$

1,688

 

 

$

2,882

 

Refractory chronic cough clinical trial expense

 

 

1,078

 

 

 

818

 

Other clinical trials and studies 1

 

 

1,553

 

 

 

48

 

Clinical trial material

 

 

1,299

 

 

 

234

 

Other clinical development expenses 2

 

 

1,523

 

 

 

1,418

 

Employee compensation (excluding stock compensation expense)

 

 

3,159

 

 

 

2,958

 

Stock-based compensation expense

 

 

2,191

 

 

 

1,208

 

Other segment items 3

 

 

2,397

 

 

 

1,899

 

Interest income, net

 

 

(1,696

)

 

 

(1,125

)

Net loss

 

$

13,192

 

 

$

10,340

 

 

 

(1) Includes expense related to the Company’s Phase 1 NDA supportive studies

(2) Includes expense related to general research and development activities, regulatory, medical affairs, and quality assurance.

(3) Includes general administrative expense, other (expense) income, net and income tax benefit.